CD34+ cells represent an effective angiogenic stem cell component and early-phase clinical trials have shown that intramyocardial administration of autologous CD34+ cells may improve the functional capacity and symptoms of angina and chronic myocardial ischemia2, 3. This evidence concerns the gene CD34 and angina pectoris.